Adding ACRIs and/or ARBs to Standard Therapy for Stable Ischemic Heart Disease: Benefits and Harms. Clinician Guide.

摘要

Patients who have chronic stable angina, or stable ischemic heart disease (IHD) with preserved left ventricular systolic function (LVSF), can remain symptomatic and at risk for fatal and nonfatal cardiovascular events, even though they may be optimally treated with standard medical therapy or revascularization. This summary does not discuss ACEI or ARB therapy for patients with currently accepted indications for these drugs, including LVSD, evidence or diagnosis of heart failure, or a diagnosis of cardiomyopathy. This summary presents the benefits and risks of supplementing standard medical therapy with ACEIs or ARBs to patients with stable IHD and preserved LVSF. It is based on a systematic review of the research conducted for this population, which included 12 trials (n=41,672).